ホーム › びまん性大細胞型B細胞リンパ腫 › ペンシルベニア
ペンシルベニアにおけるびまん性大細胞型B細胞リンパ腫の臨床試験
ペンシルベニア内の拠点で、びまん性大細胞型B細胞リンパ腫に関する19件の研究が参加者を募集しています。
ペンシルベニア内の都市
公式研究テキスト（英語）
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Thomas Jefferson University Hospital, Philadelphia
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06649812Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Philadelphia, Philadelphia
被験者募集中観察研究
0歳〜38歳 · 全性別 · 2026/10/01更新 · NCT06131801A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Abramson Cancer Center and Perelman Center for Advanced Medicine ( Site 0131), Philadelphia
- Temple University Hospital ( Site 0133), Philadelphia
- Alliance Cancer Specialists (ACS) ( Site 8010), Sellersville
- 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06890884A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Alliance Cancer Specialists (ACS) ( Site 8001), Horsham
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05139017A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Pennsylvania Abramson Cancer Center, Philadelphia
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia
被験者募集中第1/2相
6 Months – 25 Years · 全性別 · 2026/09/17更新 · NCT06395103Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Fox Chase Cancer Center, Philadelphia
- West Penn Hospital, Pittsburgh
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/31更新 · NCT06500273Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Lehigh Valley Topper Cancer Center Institute, Allentown
- Thomas Jefferson University, Philadelphia
- West Penn Hospital, Pittsburgh
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT05826535A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT04104776A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Allegheny Health Network, Pittsburgh
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/04更新 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Allegheny Health Network Cancer Institute, Pittsburgh
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/13更新 · NCT04792489Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
- University of Pennsylvania / Abramson Cancer Center, Philadelphia
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/10更新 · NCT05077527A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/02更新 · NCT05131022Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
- Abramson Cancer Center, University of Pennsylvania, Philadelphia
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/01更新 · NCT07478848Epcoritamab-CAR T Cells for Large B-cell Lymphomas
- Abramson Cancer Center at the University of Pennsylvania, Philadelphia
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/27更新 · NCT06458439SynKIR-310 for Relapsed/Refractory B-NHL
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/14更新 · NCT06544265Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Geisinger Medical Center, Danville
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/02更新 · NCT05633615Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
- AHN Cancer Institute - West Penn Hospital, Pittsburgh
被験者募集中第2相
18歳〜79歳 · 全性別 · 2025/01/13更新 · NCT05281809DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Allegheny Health Network (AHN) West Penn Hospital, Pittsburgh
- Reading Hospital - McGlinn Cancer Institute, West Reading
被験者募集中第2相
18歳以上 · 全性別 · 2023/04/07更新 · NCT04920617ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。